Published in Cancer Res on October 15, 2004
Breast cancer cells produce tenascin C as a metastatic niche component to colonize the lungs. Nat Med (2011) 4.25
The extracellular matrix in development and morphogenesis: a dynamic view. Dev Biol (2009) 2.82
The role of tenascin-C in tissue injury and tumorigenesis. J Cell Commun Signal (2009) 1.72
Advances in tenascin-C biology. Cell Mol Life Sci (2011) 1.50
Tenascins and the importance of adhesion modulation. Cold Spring Harb Perspect Biol (2011) 1.29
Tenascin C induces epithelial-mesenchymal transition-like change accompanied by SRC activation and focal adhesion kinase phosphorylation in human breast cancer cells. Am J Pathol (2011) 1.16
The role of cancer-associated fibroblasts, solid stress and other microenvironmental factors in tumor progression and therapy resistance. Cancer Cell Int (2014) 1.11
Matricellular proteins: a sticky affair with cancers. J Oncol (2012) 1.10
IGF-I induced genes in stromal fibroblasts predict the clinical outcome of breast and lung cancer patients. BMC Med (2010) 0.94
Future perspectives of prostate cancer therapy. Transl Androl Urol (2012) 0.91
A novel family of cyst proteins with epidermal growth factor repeats in Giardia lamblia. PLoS Negl Trop Dis (2010) 0.87
Tenascin-C: Exploitation and collateral damage in cancer management. Cell Adh Migr (2015) 0.85
Association of invasion-promoting tenascin-C additional domains with breast cancers in young women. Breast Cancer Res (2010) 0.84
Gene expression profile and toxic effects in human bronchial epithelial cells exposed to zearalenone. PLoS One (2014) 0.82
Tenascin C in metastasis: A view from the invasive front. Cell Adh Migr (2015) 0.81
Identification of proteins with potential osteogenic activity present in the water-soluble matrix proteins from Crassostrea gigas nacre using a proteomic approach. ScientificWorldJournal (2012) 0.79
Mechanistic evaluation and transcriptional signature of a glutathione S-transferase omega 1 inhibitor. Nat Commun (2016) 0.75
MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med (2005) 29.65
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol (2009) 25.96
Chromosome-wide and promoter-specific analyses identify sites of differential DNA methylation in normal and transformed human cells. Nat Genet (2005) 15.37
DNA-binding factors shape the mouse methylome at distal regulatory regions. Nature (2011) 8.75
Interferon signaling and treatment outcome in chronic hepatitis C. Proc Natl Acad Sci U S A (2008) 8.56
Bacterial disease resistance in Arabidopsis through flagellin perception. Nature (2004) 7.74
Stem cell-related "self-renewal" signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma. J Clin Oncol (2008) 6.41
Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncol (2012) 5.71
Chemokine receptor CXCR4 downregulated by von Hippel-Lindau tumour suppressor pVHL. Nature (2003) 5.57
Tenascin-C is an endogenous activator of Toll-like receptor 4 that is essential for maintaining inflammation in arthritic joint disease. Nat Med (2009) 3.87
The estrogen-related receptor alpha (ERRalpha) functions in PPARgamma coactivator 1alpha (PGC-1alpha)-induced mitochondrial biogenesis. Proc Natl Acad Sci U S A (2004) 3.65
Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3. Lancet Oncol (2007) 3.53
Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial. J Clin Oncol (2013) 3.52
MGMT promoter methylation in malignant gliomas: ready for personalized medicine? Nat Rev Neurol (2009) 3.32
Repressive and active histone methylation mark distinct promoters in human and mouse spermatozoa. Nat Struct Mol Biol (2010) 3.07
Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. J Clin Oncol (2010) 3.05
Effects of Dicer and Argonaute down-regulation on mRNA levels in human HEK293 cells. Nucleic Acids Res (2006) 2.96
Chemoradiotherapy in malignant glioma: standard of care and future directions. J Clin Oncol (2007) 2.93
Genome-wide analysis of gene expression reveals function of the bZIP transcription factor HY5 in the UV-B response of Arabidopsis. Proc Natl Acad Sci U S A (2004) 2.88
Validation of real-time methylation-specific PCR to determine O6-methylguanine-DNA methyltransferase gene promoter methylation in glioma. J Mol Diagn (2008) 2.71
DNA replication-timing analysis of human chromosome 22 at high resolution and different developmental states. Proc Natl Acad Sci U S A (2004) 2.66
CONSTITUTIVELY PHOTOMORPHOGENIC1 is required for the UV-B response in Arabidopsis. Plant Cell (2006) 2.57
CD24 expression causes the acquisition of multiple cellular properties associated with tumor growth and metastasis. Cancer Res (2005) 2.53
Changing paradigms--an update on the multidisciplinary management of malignant glioma. Oncologist (2006) 2.42
Interaction of COP1 and UVR8 regulates UV-B-induced photomorphogenesis and stress acclimation in Arabidopsis. EMBO J (2009) 2.40
Tenascin-C induced signaling in cancer. Cancer Lett (2006) 2.21
Human cytomegalovirus escapes a naturally occurring neutralizing antibody by incorporating it into assembling virions. Cell Host Microbe (2011) 2.20
Classification of human astrocytic gliomas on the basis of gene expression: a correlated group of genes with angiogenic activity emerges as a strong predictor of subtypes. Cancer Res (2003) 2.15
Control of nutrient-sensitive transcription programs by the unconventional prefoldin URI. Science (2003) 2.15
Chromatin state marks cell-type- and gender-specific replication of the Drosophila genome. Genes Dev (2009) 2.08
Retracted Marker-independent identification of glioma-initiating cells. Nat Methods (2010) 1.84
Comparative transcriptomics of rice reveals an ancient pattern of response to microbial colonization. Proc Natl Acad Sci U S A (2005) 1.74
MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status. Acta Neuropathol (2012) 1.74
Anti-O6-methylguanine-methyltransferase (MGMT) immunohistochemistry in glioblastoma multiforme: observer variability and lack of association with patient survival impede its use as clinical biomarker. Brain Pathol (2008) 1.74
The role of tenascin-C in tissue injury and tumorigenesis. J Cell Commun Signal (2009) 1.72
WNT signaling enhances breast cancer cell motility and blockade of the WNT pathway by sFRP1 suppresses MDA-MB-231 xenograft growth. Breast Cancer Res (2009) 1.70
Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q testing for malignant glioma patients in clinical practice. Neuro Oncol (2012) 1.68
Position dependencies in transcription factor binding sites. Bioinformatics (2007) 1.60
Accessibility of the Drosophila genome discriminates PcG repression, H4K16 acetylation and replication timing. Nat Struct Mol Biol (2010) 1.57
Methylguanine methyltransferase testing in glioblastoma: when and how? J Clin Oncol (2007) 1.54
Anoxia induces macrophage inhibitory cytokine-1 (MIC-1) in glioblastoma cells independently of p53 and HIF-1. Oncogene (2002) 1.52
Targeting fibroblast growth factor receptors blocks PI3K/AKT signaling, induces apoptosis, and impairs mammary tumor outgrowth and metastasis. Cancer Res (2010) 1.51
Advances in tenascin-C biology. Cell Mol Life Sci (2011) 1.50
Suppression of RNA silencing by a geminivirus nuclear protein, AC2, correlates with transactivation of host genes. J Virol (2005) 1.46
DNA fingerprinting of glioma cell lines and considerations on similarity measurements. Neuro Oncol (2012) 1.44
The evolution of extracellular matrix. Mol Biol Cell (2010) 1.40
Pathway analysis of glioblastoma tissue after preoperative treatment with the EGFR tyrosine kinase inhibitor gefitinib--a phase II trial. Mol Cancer Ther (2011) 1.39
A versatile toolkit to produce sensitive FRET biosensors to visualize signaling in time and space. Sci Signal (2013) 1.37
Molecular neuro-oncology in clinical practice: a new horizon. Lancet Oncol (2013) 1.37
Optimal role of temozolomide in the treatment of malignant gliomas. Curr Neurol Neurosci Rep (2005) 1.36
Sex-specific role of Drosophila melanogaster HP1 in regulating chromatin structure and gene transcription. Nat Genet (2005) 1.35
Tenascin-C is a novel RBPJkappa-induced target gene for Notch signaling in gliomas. Cancer Res (2009) 1.34
Presence of alternative lengthening of telomeres mechanism in patients with glioblastoma identifies a less aggressive tumor type with longer survival. J Neuropathol Exp Neurol (2010) 1.32
Epidermal growth factor receptor inhibitors in neuro-oncology: hopes and disappointments. Clin Cancer Res (2008) 1.32
New prognostic factors and calculators for outcome prediction in patients with recurrent glioblastoma: a pooled analysis of EORTC Brain Tumour Group phase I and II clinical trials. Eur J Cancer (2012) 1.31
Recent developments in the use of chemotherapy in brain tumours. Eur J Cancer (2006) 1.24
Presence of an oligodendroglioma-like component in newly diagnosed glioblastoma identifies a pathogenetically heterogeneous subgroup and lacks prognostic value: central pathology review of the EORTC_26981/NCIC_CE.3 trial. Acta Neuropathol (2012) 1.22
A safety run-in and randomized phase 2 study of cilengitide combined with chemoradiation for newly diagnosed glioblastoma (NABTT 0306). Cancer (2012) 1.21
Modulation of angiogenic and inflammatory response in glioblastoma by hypoxia. PLoS One (2009) 1.19
Mutations in Lama1 disrupt retinal vascular development and inner limiting membrane formation. J Biol Chem (2010) 1.19
Interfering with the connection between the nucleus and the cytoskeleton affects nuclear rotation, mechanotransduction and myogenesis. Int J Biochem Cell Biol (2010) 1.17
LMX1B mutations cause hereditary FSGS without extrarenal involvement. J Am Soc Nephrol (2013) 1.16
Elevated levels of MIC-1/GDF15 in the cerebrospinal fluid of patients are associated with glioblastoma and worse outcome. Int J Cancer (2009) 1.16
The regulation of tenascin expression by tissue microenvironments. Biochim Biophys Acta (2008) 1.15
Overestimation of alternative splicing caused by variable probe characteristics in exon arrays. Nucleic Acids Res (2009) 1.13
Fibronectin and tenascin-C: accomplices in vascular morphogenesis during development and tumor growth. Int J Dev Biol (2011) 1.13
Heterochromatin protein 1 (HP1) modulates replication timing of the Drosophila genome. Genome Res (2010) 1.12
Collagen XII interacts with avian tenascin-X through its NC3 domain. J Biol Chem (2006) 1.10
The Wnt inhibitory factor 1 (WIF1) is targeted in glioblastoma and has a tumor suppressing function potentially by induction of senescence. Neuro Oncol (2011) 1.10
Non-genotoxic carcinogen exposure induces defined changes in the 5-hydroxymethylome. Genome Biol (2012) 1.09
Molecular diagnostics of gliomas: the clinical perspective. Acta Neuropathol (2010) 1.08
Evidence for the evolution of tenascin and fibronectin early in the chordate lineage. Int J Biochem Cell Biol (2008) 1.06
RGD-independent cell adhesion via a tissue transglutaminase-fibronectin matrix promotes fibronectin fibril deposition and requires syndecan-4/2 α5β1 integrin co-signaling. J Biol Chem (2010) 1.05
Dynamic response of plant genome to ultraviolet radiation and other genotoxic stresses. Mutat Res (2005) 1.04
Extent and patterns of MGMT promoter methylation in glioblastoma- and respective glioblastoma-derived spheres. Clin Cancer Res (2010) 1.02
Tenascin-W is found in malignant mammary tumors, promotes alpha8 integrin-dependent motility and requires p38MAPK activity for BMP-2 and TNF-alpha induced expression in vitro. Oncogene (2005) 1.02
Role of laminins in physiological and pathological angiogenesis. Int J Dev Biol (2011) 1.01
Teneurin-1 is expressed in interconnected regions of the developing brain and is processed in vivo. BMC Dev Biol (2008) 1.01
Identification of the C3a receptor (C3AR1) as the target of the VGF-derived peptide TLQP-21 in rodent cells. J Biol Chem (2013) 1.00
Teneurin 2 is expressed by the neurons of the thalamofugal visual system in situ and promotes homophilic cell-cell adhesion in vitro. Development (2002) 1.00
New trends in the medical management of glioblastoma multiforme: the role of temozolomide chemotherapy. Neurosurg Focus (2006) 0.99
Tenascin-C blocks cell-cycle progression of anchorage-dependent fibroblasts on fibronectin through inhibition of syndecan-4. Oncogene (2003) 0.98
MGMT methylation status: the advent of stratified therapy in glioblastoma? Dis Markers (2007) 0.98
MGMT promoter methylation in malignant gliomas. Target Oncol (2010) 0.97
TGF-β-induced differentiation into myofibroblasts involves specific regulation of two MKL1 isoforms. J Cell Sci (2014) 0.97
Caenorhabditis elegans teneurin, ten-1, is required for gonadal and pharyngeal basement membrane integrity and acts redundantly with integrin ina-1 and dystroglycan dgn-1. Mol Biol Cell (2008) 0.97